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Introduction
Epidemics of influenza typically occur during the winter
months and are responsible for an average of approximately
20,000 deaths/year in the United States (1,2). Influenza
viruses also can cause pandemics, during which rates of illness
and death from influenza-related complications can increase
dramatically worldwide. Influenza viruses cause disease among
all age groups (3–5). Rates of infection are highest among chil-
dren, but rates of serious illness and death are highest among
persons aged >65 years and persons of any age who have medi-
cal conditions that place them at increased risk for complica-
tions from influenza (3,6–8).
Influenza vaccination is the primary method for preventing
influenza and its severe complications. In this report from the
Advisory Committee on Immunization Practices (ACIP), the
primary target groups recommended for annual vaccination
are 1) groups who are at increased risk for influenza-related
complications (e.g., persons aged >65 years and persons of
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Summary
This report updates the 2001 recommendations by the Advisory Committee on Immunization Practices (ACIP) regarding the
use of influenza vaccine and antiviral agents (MMWR 2001;50[No. RR-4]:1–44). The 2002 recommendations include new or
updated information regarding 1) the timing of influenza vaccination by risk group; 2) influenza vaccine for children aged 6–23
months; 3) the 2002–2003 trivalent vaccine virus strains: A/Moscow/10/99 (H3N2)-like, A/New Caledonia/20/99 (H1N1)-
like, and B/Hong Kong/330/2001-like strains; and 4) availability of certain influenza vaccine doses with reduced thimerosal
content. A link to this report and other information related to influenza can be accessed at the website for the Influenza Branch,
Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC, at http://www.cdc.gov/ncidod/diseases/
flu/fluvirus.htm.
any age with certain chronic medical conditions); 2) persons
aged 50–64 years, because this group has an elevated preva-
lence of certain chronic medical conditions; and 3) persons
who live with or care for persons at high risk (e.g., health-care
workers and household members who have frequent contact
with persons at high risk and can transmit influenza to per-
sons at high risk). Vaccination is associated with reductions in
influenza-related respiratory illness and physician visits among
all age groups, hospitalization and death among persons at
high risk, otitis media among children, and work absenteeism
among adults (9–18). Although influenza vaccination levels
increased substantially during the 1990s, further improvements
in vaccine coverage levels are needed, chiefly among persons
aged <65 years at high risk. The ACIP recommends using strat-
egies to improve vaccination levels, including using reminder/
recall systems and standing orders programs (19,20). Although
influenza vaccination remains the cornerstone for the control
and treatment of influenza, information is also presented
regarding antiviral medications, because these agents are an
adjunct to vaccine.
Primary Changes and Updates
in the Recommendations
The 2002 recommendations include five principal changes
or updates, as follows:
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1. The optimal time to receive influenza vaccine is during
October and November. However, because of vaccine
distribution delays during the past 2 years, ACIP
recommends that vaccination efforts in October focus
on persons at greatest risk for influenza-related
complications and health-care workers and that
vaccination of other groups begin in November.
2. Vaccination efforts for all groups should continue into
December and later, for as long as vaccine is available.
3. Because young, otherwise healthy children are at increased
risk for influenza-related hospitalization, influenza
vaccination of healthy children aged 6–23 months is
encouraged when feasible. Vaccination of children aged
>6 months who have certain medical conditions continues
to be strongly recommended.
4. The 2002–2003 trivalent vaccine virus strains are
A/Moscow/10/99 (H3N2)-like, A/New Caledonia/20/99
(H1N1)-like, and B/Hong Kong/330/2001-like strains.
5. A limited amount of influenza vaccine with reduced
thimerosal content will be available for the 2002–2003
influenza season.
Influenza and Its Burden
Biology of Influenza
Influenza A and B are the two types of influenza viruses that
cause epidemic human disease (21). Influenza A viruses are
further categorized into subtypes on the basis of two surface
antigens: hemagglutinin (H) and neuraminidase (N). Influ-
enza B viruses are not categorized into subtypes. Since 1977,
influenza A (H1N1) viruses, influenza A (H3N2) viruses, and
influenza B viruses have been in global circulation. Influenza
A (H1N2) viruses that probably emerged after genetic
reassortment between human A (H3N2) and A (H1N1)
viruses have been detected recently in many countries. Both
influenza A and B viruses are further separated into groups on
the basis of antigenic characteristics. New influenza virus vari-
ants result from frequent antigenic change (i.e., antigenic drift)
resulting from point mutations that occur during viral repli-
cation. Influenza B viruses undergo antigenic drift less rapidly
than influenza A viruses.
A person’s immunity to the surface antigens, especially
hemagglutinin, reduces the likelihood of infection and sever-
ity of disease if infection occurs (22). Antibody against one
influenza virus type or subtype confers limited or no protec-
tion against another. Furthermore, antibody to one antigenic
variant of influenza virus might not protect against a new
antigenic variant of the same type or subtype (23). Frequent
development of antigenic variants through antigenic drift is
the virologic basis for seasonal epidemics and the reason for
the incorporation of >1 new strains in each year’s influenza
vaccine.
Clinical Signs and Symptoms of Influenza
Influenza viruses are spread from person-to-person prima-
rily through the coughing and sneezing of infected persons
(21). The incubation period for influenza is 1–4 days, with an
average of 2 days (24). Adults and children typically are infec-
tious from the day before symptoms begin until approximately
5 days after illness onset. Children can be infectious for a longer
period, and very young children can shed virus for <6 days
before their illness onset. Severely immunocompromised per-
sons can shed virus for weeks (25–27).
Uncomplicated influenza illness is characterized by the
abrupt onset of constitutional and respiratory signs and symp-
toms (e.g., fever, myalgia, headache, severe malaise, nonpro-
ductive cough, sore throat, and rhinitis) (28). Respiratory illness
caused by influenza is difficult to distinguish from illness
caused by other respiratory pathogens on the basis of symp-
toms alone (see Role of Laboratory Diagnosis). Reported sen-
sitivities and specificities of clinical definitions for
influenza-like illness that include fever and cough have ranged
from 63% to 78% and 55% to 71%, respectively, compared
with viral culture (29,30). Sensitivity and predictive value of
clinical definitions can vary, depending on the degree of
co-circulation of other respiratory pathogens and the level of
influenza activity (31).
Influenza illness typically resolves after a limited number of
days for the majority of persons, although cough and malaise
can persist for >2 weeks. Among certain persons, influenza
can exacerbate underlying medical conditions (e.g., pulmo-
nary or cardiac disease), lead to secondary bacterial pneumo-
nia or primary influenza viral pneumonia, or occur as part of
a coinfection with other viral or bacterial pathogens (32).
Influenza infection has also been associated with encephal-
opathy, transverse myelitis, Reye syndrome, myositis,
myocarditis, and pericarditis (32).
Hospitalizations and Deaths from Influenza
The risks for complications, hospitalizations, and deaths
from influenza are higher among persons aged >65 years, very
young children, and persons of any age with certain under-
lying health conditions than among healthy older children
and younger adults (1,2,7,9,33–35). Estimated rates of influenza-
associated hospitalizations have varied substantially by
age group in studies conducted during different influenza
epidemics (Table 1).
Among children aged 0–4 years, hospitalization rates have
ranged from approximately 500/100,000 population for those
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TABLE 1. Estimated rates of influenza-associated hospitalization by age group and risk group from selected studies.*
Hospitalizations/ Hospitalizations/
100,000 persons 100,000 persons
with high-risk without high-risk
Study years Population Age Group conditions conditions
1973–1993†§ Tennessee 0–11 mos 1,900 496–1,038¶
1973–1993§** Medicaid 1–2 yrs 800 186
3–4 yrs 320 86
5–14 yrs 92 41
1992–1997†† §§ Two Health 0–23 mos 144–187
Maintenance 2–4 yrs 0–25
Organizations 5–17 yrs 8–12
1968–1969,¶¶ *** Health 15–44 yrs 56–110 23–25
1970–1971, Maintenance 45–64 yrs 392–635 13–23
1972–1973 Organization >65 yrs 399–518 —
1969–1995††† *** National <65 yrs —§§§ 20–42§§§ ¶¶¶
Hospital >65 yrs — 125–228¶¶¶
Discharge
Data
* Rates were estimated in years and populations with low vaccination rates. Hospitalization rates can be expected to decrease as vaccination rates
increased. Vaccination can be expected to reduce influenza-related hospitalizations by 30%–70% among older persons and likely by even higher percent-
ages among younger age groups when vaccine and circulating influenza virus strains are antigenically similar.
† Source: Neuzil KM, Mellen BG, Wright PF, Mitchel EF, Griffin MR. Effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in
children. New Engl J Med 2000;342:225–31.
§ Outcomes were for acute cardiac or pulmonary conditions.
¶ The low estimate is for infants aged 6–11 months, and the high estimate is for infants aged 0–5 months.
** Source: Neuzil KM, Wright PF, Mitchel EF, Griffin MR. Burden of influenza illness in children with asthma andother chronic medical conditions. J Pediatr
2000;137:856–64.
†† Source: Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children.
New Engl J Med 2000;342:232–9.
§§ Outcomes were for acute pulmonary conditions. Influenza-attributable hospitalization rates for children at high risk were not included in this study.
¶¶ Source: Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 1980;112:798–811.
*** Outcomes were limited to hospitalizations in which either pneumonia or influenza was listed as the first condition on discharge records (Simonsen) or
included anywhere in the list of discharge diagnoses (Barker).
††† Source: Simonsen L, Fukuda, K, Schonberger LB, Cox NJ. Impact of influenza epidemics on hospitalizations. J Infect Dis 2000;181:831–7.
§§§ Persons at high risk and not at high risk are combined.
¶¶¶ The low estimate is the average during influenza A(H1N1) or influenza B-predominate seasons, and the high estimate is the average during influenza A
(H3N2)-predominate seasons.
with high-risk conditions to 100/100,000 population for those
without high-risk conditions (36–39). Within the 0–4 age
group, hospitalization rates are highest among children aged
0–1 years and are comparable to rates found among persons
aged >65 years (38,39) (Table 1).
During influenza epidemics from 1969–1970 through
1994–1995, the estimated overall number of influenza-
associated hospitalizations in the United States ranged from
approximately 16,000 to 220,000/epidemic. An average of
approximately 114,000 influenza-related excess hospitaliza-
tions occurred per year, with 57% of all hospitalizations oc-
curring among persons aged <65 years. Since the 1968
influenza A (H3N2) virus pandemic, the greatest numbers of
influenza-associated hospitalizations have occurred during
epidemics caused by type A (H3N2) viruses, with an estimated
average of 142,000 influenza-associated hospitalizations per
year (40).
Influenza-related deaths can result from pneumonia as well
as from exacerbations of cardiopulmonary conditions and other
chronic diseases. In studies of influenza epidemics occurring
from 1972–1973 through 1994–1995, excess deaths (i.e., the
number of influenza-related deaths above a projected baseline
of expected deaths) occurred during 19 of 23 influenza epi-
demics (41) (unpublished data, Influenza Branch, Division of
Viral and Rickettsial Diseases [DVRD], National Center for
Infectious Diseases [NCID], CDC, 1998). During those 19
influenza seasons, estimated rates of influenza-associated deaths
ranged from approximately 30 to >150 deaths/100,000 per-
sons aged >65 years (unpublished data, Influenza Branch,
DVRD, NCID, CDC, 1998). Older adults account for >90%
of deaths attributed to pneumonia and influenza (42).
From 1972–1973 through 1994–1995, >20,000 influenza-
associated deaths were estimated to occur during each of 11
different U.S. epidemics, and >40,000 influenza-associated
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deaths were estimated for each of 6 of these 11 epidemics (41)
(unpublished data, Influenza Branch, DVRD, NCID, CDC,
1998). In the United States, pneumonia and influenza deaths
might be increasing in part because the number of older
persons is increasing (43).
Options for Controlling Influenza
In the United States, the main option for reducing the
impact of influenza is immunoprophylaxis with inactivated
(i.e., killed virus) vaccine (see Recommendations for Using
Influenza Vaccine). Vaccinating persons at high risk for com-
plications each year before seasonal increases in influenza
virus circulation is the most effective means of reducing the
impact of influenza. Vaccination coverage can be increased by
administering vaccine to persons during hospitalizations or
routine health-care visits before the influenza season, render-
ing special visits to physicians’ offices or clinics unnecessary.
When vaccine and epidemic strains are well-matched, achiev-
ing increased vaccination rates among persons living in closed
settings (e.g., nursing homes and other chronic-care facilities)
and among staff can reduce the risk for outbreaks by inducing
herd immunity (14). Vaccination of health-care workers and
other persons in close contact with persons in groups at high
risk can also reduce transmission of influenza and subsequent
influenza-related complications. Using influenza-specific
antiviral drugs for chemoprophylaxis or treatment of influ-
enza is a key adjunct to vaccine (see Recommendations for
Using Antiviral Agents for Influenza). However, antiviral medi-
cations are not a substitute for vaccination.
Influenza Vaccine Composition
Influenza vaccines are standardized to contain the hemag-
glutinins of strains (i.e., typically two type A and one type B),
representing the influenza viruses likely to circulate in the
United States in the upcoming winter. The vaccine is made
from highly purified, egg-grown viruses that have been made
noninfectious (i.e., inactivated) (44). Subvirion and purified
surface-antigen preparations are available. Because the vaccine
viruses are initially grown in embryonated hens’ eggs, the vac-
cine might contain limited amounts of residual egg protein.
Manufacturing processes differ by manufacturer. Manufac-
turers might use different compounds to inactivate influenza
viruses and add antibiotics to prevent bacterial contamina-
tion. Package inserts should be consulted for additional
information.
Influenza vaccine distributed in the United States might also
contain thimerosal, a mercury-containing compound, as the
preservative (45). Thimerosal has been used as a preservative
in vaccines since the 1930s. Although no evidence of harm
caused by low levels of thimerosal in vaccines has been
reported, in 1999, the U.S. Public Health Service and other
organizations recommended that efforts be made to reduce
the thimerosal content in vaccines to decrease total mercury
exposure, chiefly among infants and pregnant woman (45,46).
Since mid-2001, routinely administered, noninfluenza child-
hood vaccines for the U.S. market have been manufactured
either without or with only trace amounts of thimerosal to
provide a substantial reduction in the total mercury exposure
from vaccines for children (47).
For the 2002–2003 influenza season, a limited number of
individually packaged doses (i.e., single-dose syringes)
of reduced thimerosal-content influenza vaccine (<1 mcg
thimerosal/0.5 mL-dose) will be available. Thus far, reduced
thimerosal content vaccine is available from one manufacturer,
Evans Vaccines. This manufacturer’s vaccine is approved for
use in persons aged >4 years (see Vaccine Use for Young Chil-
dren, By Manufacturer). Multidose vials and single-dose
syringes of influenza vaccine containing approximately 25 mcg
thimerosal/0.5 mL-dose are also available as they have been in
past years. Because of the known risks for severe illness from
influenza infection and the benefits of vaccination, and
because a substantial safety margin has been incorporated into
the health guidance values for organic mercury exposure,
the benefit of influenza vaccine with reduced or standard
thimerosal content outweighs the theoretical risk, if any, from
thimerosal (45,48). The removal of thimerosal from other vac-
cines further reduces the theoretical risk from thimerosal in
influenza vaccines.
The trivalent influenza vaccine recommended for the 2002–
2003 season includes A/Moscow/10/99 (H3N2)-like, A/New
Caledonia/20/99 (H1N1)-like, and B/Hong Kong/330/2001-
like antigens. For the A/Moscow/10/99 (H3N2)-like antigen,
manufacturers will use the antigenically equivalent A/Panama/
2007/99 (H3N2) virus. For the B/Hong Kong/330/2001-like
antigen, the actual B strains that will be included in the
vaccine will be announced later. These viruses will be used
because of their growth properties and because they are repre-
sentative of influenza viruses likely to circulate in the United
States during the 2002–2003 influenza season. Because circu-
lating influenza A (H1N2) viruses are a reasortant of influ-
enza A (H1N1) and (H3N2) viruses, antibody directed against
influenza A (H1N1) and influenza (H3N2) vaccine strains
will provide protection against circulating influenza A (H1N2)
viruses.
Effectiveness of Inactivated Influenza Vaccine
The effectiveness of influenza vaccine depends primarily on
the age and immunocompetence of the vaccine recipient and
the degree of similarity between the viruses in the vaccine and
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those in circulation. The majority of vaccinated children and
young adults develop high postvaccination hemagglutination-
inhibition antibody titers (49–51). These antibody titers are
protective against illness caused by strains similar to those in
the vaccine (50–53). When the vaccine and circulating
viruses are antigenically similar, influenza vaccine prevents
influenza illness among approximately 70%–90% of healthy
adults aged <65 years (10,13,54,55). Vaccination of healthy
adults also has resulted in decreased work absenteeism and
decreased use of health-care resources, including use of
antibiotics, when the vaccine and circulating viruses are
well-matched (10–13,55,56).
Children as young as age 6 months can develop protective
levels of antibody after influenza vaccination (49,50,57–60),
although the antibody response among children at high risk
might be lower than among healthy children (61,62). In a
randomized study among children aged 1–15 years, inacti-
vated influenza vaccine was 77%–91% effective against influ-
enza respiratory illness and was 44%–49%, 74%–76%, and
70%–81% effective against influenza seroconversion among
children aged 1–5, 6–10, and 11–15 years, respectively (51).
One study (63) reported a vaccine efficacy of 56% against
influenza illness among healthy children aged 3–9 years, and
another study (64) found vaccine efficacy of 22%–54% and
60%–78% among children with asthma aged 2–6 years and
7–14 years, respectively. A 2-year randomized study of chil-
dren aged 6–24 months determined that >89% of children
seroconverted to all three vaccine strains during both years;
vaccine efficacy was 66% (95% confidence intervals [CI] =
34% and 82%) against culture-confirmed influenza during
year 1 among 411 children and was –7% (95% CI = –247%
and 67%) during year 2 among 375 children. However, no
overall reduction in otitis media was reported (65). Other stud-
ies report that using trivalent inactivated influenza vaccine
decreases the incidence of influenza-associated otitis media
among young children by approximately 30% (17,18).
Older persons and persons with certain chronic diseases
might develop lower postvaccination antibody titers than
healthy young adults and thus can remain susceptible to
influenza-related upper respiratory tract infection (66–68). A
randomized trial among noninstitutionalized persons aged >60
years reported a vaccine efficacy of 58% against influenza res-
piratory illness, but indicated that efficacy might be lower
among those aged >70 years (69). The vaccine can also be
effective in preventing secondary complications and reducing
the risk for influenza-related hospitalization and death (14–
16,70). Among elderly persons living outside nursing homes
or similar chronic-care facilities, influenza vaccine is 30%–
70% effective in preventing hospitalization for pneumonia and
influenza (16,71). Among elderly persons residing in nursing
homes, influenza vaccine is most effective in preventing
severe illness, secondary complications, and deaths. Among
this population, the vaccine can be 50%–60% effective in pre-
venting hospitalization or pneumonia and 80% effective in
preventing death, although the effectiveness in preventing
influenza illness often ranges from 30% to 40% (72,73).
Cost-Effectiveness of Influenza Vaccine
Influenza vaccination can reduce both health-care costs and
productivity losses associated with influenza illness. Economic
studies of influenza vaccination of persons aged >65 years con-
ducted in the United States have reported overall societal cost-
savings and substantial reductions in hospitalization and death
(16,71,74). Studies of adults aged <65 years have reported
that vaccination can reduce both direct medical costs and
indirect costs from work absenteeism (9,11–13,55). Reduc-
tions of 34%–44% in physician visits, 32%–45% in lost work-
days (11,13), and 25% in antibiotic use for influenza-associated
illnesses have been reported (13). One cost-effectiveness analy-
sis estimated a cost of approximately $60–$4,000/illness
averted among healthy persons aged 18–64 years, depending
on the cost of vaccination, the influenza attack rate, and vac-
cine effectiveness against influenza-like illness (55). Another
cost-benefit economic model estimated an average annual sav-
ings of $13.66/person vaccinated (75). In the second study,
78% of all costs prevented were costs from lost work produc-
tivity, whereas the first study did not include productivity losses
from influenza illness. Economic studies specifically evaluat-
ing the cost-effectiveness of vaccinating persons aged 50–64
years are not available, and the number of studies that exam-
ine the economics of routinely vaccinating children are lim-
ited (9,76–78). However, in a study that included all age
groups, cost-utility improved with increasing age and among
those with chronic medical conditions (9). Among persons
aged >65 years, vaccination resulted in a net savings per
quality-adjusted-life-year (QALY) gained and resulted in costs
of $23–$256/QALY among younger age groups. Additional
studies of the relative cost-effectiveness and cost-utility of
influenza vaccination among children and among adults aged
<65 years are needed and should be designed to account for
year-to-year variations in influenza attack rates, illness sever-
ity, and vaccine efficacy when evaluating the long-term costs
and benefits of annual vaccination.
Vaccination Coverage Levels
Among persons aged >65 years, influenza vaccination levels
increased from 33% in 1989 (79) to 66% in 1999 (80), sur-
passing the Healthy People 2000 goal of 60% (81). Although
1999 influenza vaccination coverage reached the highest lev-
els recorded among black, Hispanic, and white populations,
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vaccination levels among blacks and Hispanics continue to
lag behind those among whites (80,82). In 1999, the influ-
enza vaccination rates among persons aged >65 years were 68%
among non-Hispanic whites, 50% among non-Hispanic
blacks, and 55% among Hispanics (80). Possible reasons for
the increase in influenza vaccination levels among persons aged
>65 years through 1999 include greater acceptance of preven-
tive medical services by practitioners, increased delivery and
administration of vaccine by health-care providers and sources
other than physicians, new information regarding influenza
vaccine effectiveness, cost-effectiveness, and safety, and the
initiation of Medicare reimbursement for influenza vaccina-
tion in 1993 (9,15,16,72,73,83,84).
Influenza vaccination levels among persons interviewed
during 2000 were not substantially different from 1999 levels
among persons aged >65 years (64% in 2000 versus 66% in
1999) and persons aged 50–64 years (35% in 2000 versus
34% in 1999) (80). The percentage of adults interviewed dur-
ing the first quarter of 2001 who reported influenza vaccina-
tion during the past 12 months was lower than the percentage
reported by adults interviewed during the first quarter of 2000
(63% versus 68% among those aged >65 years; 32% versus
37% among those aged 50–64 years). Delays in influenza vac-
cine supply during fall 2000 probably contributed to these
declines in vaccination levels (see Vaccine Supply). Contin-
ued annual monitoring is needed to determine the effects of
vaccine supply delays and other factors on vaccination cover-
age among persons aged >50 years. The Healthy People 2010
objective is to achieve vaccination coverage for 90% of per-
sons aged >65 years (85). Additional strategies are needed to
achieve this Healthy People 2010 objective in all segments of
the population and to reduce racial and ethnic disparities in
vaccine coverage.
In 1997 and 1998, vaccination rate estimates among nurs-
ing home residents were 64%–82% and 83%, respectively
(86,87). The Healthy People 2010 goal is to achieve influenza
vaccination of 90% of nursing home residents, an increase
from the Healthy People 2000 goal of 80% (81,85).
In 2000, the overall vaccination rate for adults aged 18–64
years with high-risk conditions was 32%, far short of the
Healthy People 2000 goal of 60% (unpublished data, National
Immunization Program [NIP], CDC, 2000) (81). Among
persons aged 50–64 years, 44% of those with chronic medical
conditions and 31% of those without chronic medical condi-
tions received influenza vaccine. Only 25% of adults aged <50
years with high-risk conditions were vaccinated.
Reported vaccination rates of children at high risk are low.
One study conducted among patients in health maintenance
organizations reported influenza vaccination rates ranging from
9% to 10% among children with asthma (88), and a rate of
25% was reported among children with severe-to-moderate
asthma who attended an allergy and immunology clinic (89).
However, a study conducted in a pediatric clinic demonstrated
an increase in the vaccination rate of children with asthma or
reactive airways disease of 5%–32% after implementing a
reminder/recall system (90). Increasing vaccination coverage
among persons who have high-risk conditions and are aged
<65 years, including children at high risk, is the highest prior-
ity for expanding influenza vaccine use.
Annual vaccination is recommended for health-care work-
ers. Nonetheless, the National Health Interview Survey (NHIS)
indicated vaccination rates of only 34% and 38% among
health-care workers in the 1997 and 2000 surveys, respectively
(91) (unpublished NHIS data, NIP, CDC, 2002). Vaccina-
tion of health-care workers has been associated with reduced
work absenteeism (10) and fewer deaths among nursing home
patients (92,93).
Limited information is available regarding the use of influ-
enza vaccine among pregnant women. Among women aged
18–44 years without diabetes responding to the 1999 Behav-
ioral Risk Factor Surveillance Survey, those reporting they were
pregnant were less likely to report influenza vaccination dur-
ing the past 12 months (9.6%) than those not pregnant
(15.7%). Vaccination coverage among pregnant women did
not substantially change during 1997–1999, whereas cover-
age among nonpregnant women increased from 14.4% in
1997. Similar results were determined by using the 1997–2000
NHIS data, excluding pregnant women who reported diabe-
tes, heart disease, lung disease, and other selected high-risk
conditions (unpublished NHIS data, NIP, CDC, 2002).
Although not directly measuring influenza vaccination among
women who were past the second trimester of pregnancy dur-
ing influenza season, these data indicate low compliance with
the ACIP recommendations for pregnant women (94). In a
study of influenza vaccine acceptance by pregnant women,
71% who were offered the vaccine chose to be vaccinated (95).
However, a 1999 survey of obstetricians and gynecologists
determined that only 39% gave influenza vaccine to obstetric
patients, although 86% agree that pregnant women’s risk for
influenza-related morbidity and mortality increases during the
last two trimesters (96).
Recommendations for Using
Influenza Vaccine
Influenza vaccine is strongly recommended for any person
aged >6 months who is at increased risk for complications
from influenza. In addition, health-care workers and other
persons (including household members) in close contact with
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persons at high risk should be vaccinated to decrease the risk
for transmitting influenza to persons at high risk. Influenza
vaccine also can be administered to any person aged >6 months
to reduce the probability of becoming infected with influenza.
Target Groups for Vaccination
Persons at Increased Risk for Complications
Vaccination is recommended for the following groups of
persons who are at increased risk for complications from
influenza:
• persons aged >65 years;
• residents of nursing homes and other chronic-care
facilities that house persons of any age who have chronic
medical conditions;
• adults and children who have chronic disorders of the
pulmonary or cardiovascular systems, including asthma;
• adults and children who have required regular medical
follow-up or hospitalization during the preceding year
because of chronic metabolic diseases (including diabetes
mellitus), renal dysfunction, hemoglobinopathies, or
immunosuppression (including immunosuppression
caused by medications or by human immunodeficiency
[HIV] virus);
• children and adolescents (aged 6 months–18 years) who
are receiving long-term aspirin therapy and, therefore,
might be at risk for developing Reye syndrome after
influenza infection; and
• women who will be in the second or third trimester of
pregnancy during the influenza season.
Approximately 35 million persons in the United States are
aged >65 years; an additional 10–14 million adults aged
50–64 years, 15–18 million adults aged 18–49 years, and 8
million children aged 6 months–17 years have >1 medical
conditions that are associated with an increased risk for
influenza-related complications (unpublished data, NIP, CDC,
2002).
Persons Aged 50–64 Years
Vaccination is recommended for persons aged 50–64 years
because this group has an increased prevalence of persons with
high-risk conditions. Approximately 43 million persons in the
United States are aged 50–64 years, and 10–14 million (24%–
32%) have >1 high-risk medical conditions (unpublished data,
NIP, CDC, 2002). Influenza vaccine has been recommended
for this entire age group to increase the low vaccination rates
among persons in this age group with high-risk conditions.
Age-based strategies are more successful in increasing vaccine
coverage than patient-selection strategies based on medical
conditions. Persons aged 50–64 years without high-risk
conditions also receive benefit from vaccination in the form
of decreased rates of influenza illness, decreased work absen-
teeism, and decreased need for medical visits and medication,
including antibiotics (10–13). Further, 50 years is an age when
other preventive services begin and when routine assessment
of vaccination and other preventive services has been recom-
mended (97,98).
Persons Who Can Transmit Influenza
to Those at High Risk
Persons who are clinically or subclinically infected can trans-
mit influenza virus to persons at high risk for complications
from influenza. Decreasing transmission of influenza from
caregivers to persons at high risk might reduce influenza-
related deaths among persons at high risk. Evidence from two
studies indicates that vaccination of health-care workers is
associated with decreased deaths among nursing home patients
(92,93). Vaccination of health-care workers and others in close
contact with persons at high risk, including household
members, is recommended. The following groups should be
vaccinated:
• physicians, nurses, and other personnel in both hospital
and outpatient-care settings, including medical emergency
response workers (e.g., paramedics and emergency medi-
cal technicians);
• employees of nursing homes and chronic-care facilities
who have contact with patients or residents;
• employees of assisted living and other residences for
persons in groups at high risk;
• persons who provide home care to persons in groups at
high risk; and
• household members (including children) of persons in
groups at high risk.
In addition, because children aged 0–23 months are at
increased risk for influenza-related hospitalization (37–39),
vaccination is encouraged for their household contacts and
out-of-home caretakers, particularly for contacts of children
aged 0–5 months because influenza vaccines have not been
approved by the U.S. Food and Drug Administration (FDA)
for use among children aged <6 months (see Healthy Young
Children).
Additional Information Regarding
Vaccination of Specific Populations
Pregnant Women
Influenza-associated excess deaths among pregnant women
were documented during the pandemics of 1918–1919 and
1957–1958 (99–102). Case reports and limited studies
also indicate that pregnancy can increase the risk for serious
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medical complications of influenza as a result of increases in
heart rate, stroke volume, and oxygen consumption; decreases
in lung capacity; and changes in immunologic function (103–
106). A study of the impact of influenza during 17
interpandemic influenza seasons demonstrated that the rela-
tive risk for hospitalization for selected cardiorespiratory con-
ditions among pregnant women enrolled in Medicaid increased
from 1.4 during weeks 14–20 of gestation to 4.7 during weeks
37–42 in comparison with women who were 1–6 months
postpartum (107). Women in their third trimester of preg-
nancy were hospitalized at a rate (i.e., 250/100,000 pregnant
women) comparable with that of nonpregnant women who
had high-risk medical conditions. By using data from this
study, researchers estimated that an average of 1–2 hospital-
izations could be prevented for every 1,000 pregnant women
vaccinated.
Because of the increased risk for influenza-related compli-
cations, women who will be beyond the first trimester of preg-
nancy (>14 weeks of gestation) during the influenza season
should be vaccinated. Certain providers prefer to administer
influenza vaccine during the second trimester to avoid a coin-
cidental association with spontaneous abortion, which is com-
mon in the first trimester, and because exposures to
vaccines traditionally have been avoided during the first tri-
mester (108). Pregnant women who have medical conditions
that increase their risk for complications from influenza should
be vaccinated before the influenza season, regardless of the
stage of pregnancy. A study of influenza vaccination of >2,000
pregnant women demonstrated no adverse fetal effects associ-
ated with influenza vaccine (109). However, additional
data are needed to confirm the safety of vaccination during
pregnancy.
The majority of influenza vaccine distributed in the United
States contains thimerosal, a mercury-containing compound,
as a preservative, but influenza vaccine with reduced thimero-
sal content might be available in limited quantities (see Influ-
enza Vaccine Composition). Thimerosal has been used in U.S.
vaccines since the 1930s. No data or evidence exists of any
harm caused by the level of mercury exposure that might
occur from influenza vaccination. Because pregnant women
are at increased risk for influenza-related complications and
because a substantial safety margin has been incorporated into
the health guidance values for organic mercury exposure,
the benefit of influenza vaccine with reduced or standard
thimerosal content outweighs the potential risk, if any, for
thimerosal (45,48).
Persons Infected with HIV
Limited information is available regarding the frequency and
severity of influenza illness or the benefits of influenza vacci-
nation among persons with HIV infection (110,111). How-
ever, a retrospective study of young and middle-aged women
enrolled in Tennessee’s Medicaid program found that the
attributable-risk for cardiopulmonary hospitalizations among
women with HIV infection was higher during influenza sea-
sons than during the peri-influenza periods. The risk for hos-
pitalization was higher for HIV-infected women than for
women with other well-recognized high-risk conditions,
including chronic heart and lung diseases (112). Another study
estimated that the risk for influenza-related death was 9.4–
14.6/10,000 persons with AIDS, compared with rates of 0.09–
0.10/10,000 among all persons aged 25–54 years and 6.4–7.0/
10,000 among persons aged >65 years (113). Other reports
demonstrate that influenza symptoms might be prolonged and
the risk for complications from influenza increased for certain
HIV-infected persons (114–116).
Influenza vaccination has been demonstrated to produce
substantial antibody titers against influenza among vaccinated
HIV-infected persons who have minimal acquired immuno-
deficiency syndrome-related symptoms and high CD4+
T-lymphocyte cell counts (117–120). A limited, randomized,
placebo-controlled trial determined that influenza vaccine was
highly effective in preventing symptomatic, laboratory-
confirmed influenza infection among HIV-infected persons
with a mean of 400 CD4+ T-lymphocyte cells/mm3; a limited
number of persons with CD4+ T-lymphocyte cell counts of
<200 were included in that study (111). A nonrandomized
study among HIV-infected persons determined that influenza
vaccination was most effective among persons with >100 CD4+
cells and among those with <30,000 viral copies of HIV type
1/mL (116). Among patients who have advanced HIV disease
and low CD4+ T-lymphocyte cell counts, influenza vaccine
might not induce protective antibody titers (119,120); a sec-
ond dose of vaccine does not improve the immune response
in these persons (120,121).
One study reported that HIV RNA levels increased tran-
siently in one HIV-infected patient after influenza infection
(122). Studies have demonstrated a transient (i.e., 2–4-week)
increase in replication of HIV-1 in the plasma or peripheral
blood mononuclear cells of HIV-infected persons after vac-
cine administration (119,123). Other studies using similar
laboratory techniques have not documented a substantial
increase in the replication of HIV (124–126). Deterioration
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of CD4+ T-lymphocyte cell counts or progression of HIV dis-
ease have not been demonstrated among HIV-infected per-
sons after influenza vaccination compared with unvaccinated
persons (120,127). Limited information is available concern-
ing the effect of antiretroviral therapy on increases in HIV
RNA levels after either natural influenza infection or influ-
enza vaccination (110,128). Because influenza can result in
serious illness and because influenza vaccination can result in
the production of protective antibody titers, vaccination will
benefit HIV-infected patients, including HIV-infected preg-
nant women.
Breast-Feeding Mothers
Influenza vaccine does not affect the safety of mothers who
are breast-feeding or their infants. Breast-feeding does not
adversely affect the immune response and is not a contraindi-
cation for vaccination.
Travelers
The risk for exposure to influenza during travel depends on
the time of year and destination. In the tropics, influenza can
occur throughout the year. In the temperate regions of the
Southern Hemisphere, the majority of influenza activity
occurs during April–September. In temperate climate zones
of the Northern and Southern Hemispheres, travelers also can
be exposed to influenza during the summer, especially when
traveling as part of organized tourist groups that include per-
sons from areas of the world where influenza viruses are circu-
lating. Persons at high risk for complications of influenza who
were not vaccinated with influenza vaccine during the preced-
ing fall or winter should consider receiving influenza vaccine
before travel if they plan to
• travel to the tropics;
• travel with organized tourist groups at any time of year;
or
• travel to the Southern Hemisphere during April–
September.
No information is available regarding the benefits of revac-
cinating persons before summer travel who were already
vaccinated in the preceding fall. Persons at high risk who
received the previous season’s vaccine before travel should be
revaccinated with the current vaccine in the following fall or
winter. Persons aged >50 years and others at high risk might
wish to consult with their physicians before embarking on
travel during the summer to discuss the symptoms and risks
for influenza and the advisability of carrying antiviral medica-
tions for either prophylaxis or treatment of influenza.
General Population
In addition to the groups for which annual influenza vacci-
nation is recommended, physicians should administer influ-
enza vaccine to any person who wishes to reduce the likelihood
of becoming ill with influenza (the vaccine can be adminis-
tered to children aged >6 months), depending on vaccine avail-
ability (see Vaccine Supply). Persons who provide essential
community services should be considered for vaccination to
minimize disruption of essential activities during influenza
outbreaks. Students or other persons in institutional settings
(e.g., those who reside in dormitories) should be encouraged
to receive vaccine to minimize the disruption of routine
activities during epidemics.
Healthy Young Children
Studies indicate that rates of hospitalization are higher among
young children than older children when influenza viruses are
in circulation (36–38,129,130). The increased rates of hospi-
talization are comparable with rates for other groups consid-
ered at high risk for influenza-related complications. However,
the interpretation of these findings has been confounded by
co-circulation of respiratory syncytial viruses, which are a cause
of serious respiratory viral illness among children and which
frequently circulate during the same time as influenza viruses
(131–133). Two recent studies have attempted to separate the
effects of respiratory syncytial viruses and influenza viruses on
rates of hospitalization among children who do not have high-
risk conditions (37,38). Both studies reported that otherwise
healthy children aged <2 years, and possibly children aged
2–4 years, are at increased risk for influenza-related hospital-
ization compared with older healthy children (Table 1). Among
the Tennessee Medicaid population during 1973–1993, healthy
children aged 6 months–<3 years had rates of influenza-
associated hospitalization comparable with or higher than rates
among children aged 3–14 years with high-risk conditions
(Table 1) (37,39).
Because children aged 6–23 months are at substantially
increased risk for influenza-related hospitalizations,
influenza vaccination of all children in this age group is
encouraged when feasible. However, before a full recommen-
dation to annually vaccinate all children aged 6–23 months
can be made, ACIP, the American Academy of Pediatrics, and
the American Academy of Family Physicians recognize that
certain key concerns must be addressed. These concerns
include increasing efforts to educate parents and providers
regarding the impact of influenza and the potential benefits
and risks of vaccination among young children, clarification
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of practical strategies for annual vaccination of children, cer-
tain ones of whom will require two doses within the same
season, and reimbursement for vaccination. ACIP will pro-
vide updated information as these concerns are addressed. A
full recommendation could be made by 2003–2005. In the
interim, ACIP continues to strongly recommend influenza
vaccination of adults and children aged >6 months who have
high-risk medical conditions.
The current inactivated influenza vaccine is not approved
by FDA for use among children aged <6 months, the pediat-
ric group at greatest risk for influenza-related complications
(37). Vaccinating their household contacts and out-of-home
caretakers might decrease the probability of influenza among
these children.
Persons Who Should Not Be Vaccinated
Inactivated influenza vaccine should not be administered to
persons known to have anaphylactic hypersensitivity to eggs
or to other components of the influenza vaccine without first
consulting a physician (see Side Effects and Adverse Reactions).
Prophylactic use of antiviral agents is an option for preventing
influenza among such persons. However, persons who have a
history of anaphylactic hypersensitivity to vaccine components
but who are also at high risk for complications from influenza
can benefit from vaccine after appropriate allergy evaluation
and desensitization. Information regarding vaccine compo-
nents can be found in package inserts from each manufac-
turer. Persons with acute febrile illness usually should not be
vaccinated until their symptoms have abated. However,
minor illnesses with or without fever do not contraindicate
the use of influenza vaccine, particularly among children with
mild upper respiratory tract infection or allergic rhinitis.
Timing of Annual Vaccination
Vaccination in October and November
The optimal time to vaccinate is usually during October–
November. However, because of substantial vaccine distribu-
tion delays during the 2000–2001 and 2001–2002 influenza
seasons and the possibility of similar situations in future years,
ACIP recommends that vaccine providers focus their vaccina-
tion efforts in October and earlier on persons at high risk and
health-care workers. Vaccination of children aged <9 years who
are receiving vaccine for the first time should also begin in
October because they need a booster dose 1 month after the
initial dose. Vaccination of all other groups should begin in
November, including household members of persons at high
risk, healthy persons aged 50–64 years, and other persons who
wish to decrease their risk for influenza infection. Materials to
assist providers in prioritizing early vaccination are available
at http://www.cdc.gov/nip/flu/Provider.htm (for information
regarding vaccination of travelers, see the Travelers section in
this report).
Vaccination in December and Later
After November, certain persons who should or want to
receive influenza vaccine remain unvaccinated. In addition,
substantial amounts of vaccine have remained unused during
the past two influenza seasons. To improve vaccine coverage
and use, chiefly among persons at high risk and health-care
workers, influenza vaccine should continue to be offered in
December and throughout the influenza season as long as vac-
cine supplies are available, even after influenza activity has
been documented in the community. In the United States,
seasonal influenza activity can begin to increase as early as
November or December, but influenza activity has not reached
peak levels in the majority of recent seasons until late Decem-
ber through early March (Table 2). Therefore, although the
timing of influenza activity can vary by region, vaccine
administered after November is likely to be beneficial in the
majority of influenza seasons. Adults develop peak antibody
protection against influenza infection 2 weeks after vaccina-
tion (134,135).
Vaccination Before October
To avoid missed opportunities for vaccination of persons at
high risk for serious complications, such persons should be
offered vaccine beginning in September during routine health-
care visits or during hospitalizations, if vaccine is available. In
facilities housing older persons (e.g., nursing homes), vacci-
nation before October typically should be avoided because
antibody levels in such persons can begin to decline within a
limited time after vaccination (136).
Timing of Organized Vaccination Campaigns
Persons planning substantial organized vaccination cam-
paigns should consider scheduling these events after mid-
October because the availability of vaccine in any location
cannot be ensured consistently in the early fall. Scheduling
campaigns after mid-October will minimize the need for can-
cellations because vaccine is unavailable. Campaigns conducted
before November should focus efforts on vaccination of per-
sons at high risk, health-care workers, and household contacts
of persons at high-risk to the extent feasible.
Dosage
Dosage recommendations vary according to age group (Table
3). Among previously unvaccinated children aged <9 years,
two doses administered >1 months apart are recommended
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TABLE 2. Month of peak influenza activity* during 25 influenza seasons — United
States, 1976–2001
Month December January February March April May
Number (%) of years
with peak influenza
activity 4 (16) 6 (24) 10 (40) 3 (12) 1 (4) 1 (4)
* The peak week of activity was defined as the week with the greatest percentage of respiratory specimens
testing positive for influenza on the basis of a 3-week moving average. Laboratory data were provided
by U.S. World Health Organization Collaborating Laboratories (unpublished data, National Center for
Infectious Diseases, CDC).
for satisfactory antibody responses. If possible, the second dose
should be administered before December. Among adults,
studies have indicated limited or no improvement in antibody
response when a second dose is administered during the same
season (137–139). Even when the current influenza vaccine
contains >1 antigens administered in previous years, annual
vaccination with the current vaccine is necessary because
immunity declines during the year after vaccination (140,141).
Vaccine prepared for a previous influenza season should not
be administered to provide protection for the current season.
Vaccine Use Among Young Children,
By Manufacturer
Providers should use influenza vaccine that has been
approved by FDA for vaccinating children aged 6 months–3
years. Influenza vaccines from Wyeth Laboratories, Inc.
(Flushield®) and Aventis Pasteur, Inc.
(Fluzone® split-virus) are approved for
use among persons aged >6 months.
Influenza vaccine from Evans Vaccines
Ltd. (Fluvirin®) is labeled in the United
States for use only among persons aged
>4 years because data to demonstrate
efficacy among younger persons have not
been provided to FDA.
Route
The intramuscular route is recommended for influenza vac-
cine. Adults and older children should be vaccinated in the
deltoid muscle. A needle length of >1 inches can be consid-
ered for these age groups because needles <1 inch might be of
insufficient length to penetrate muscle tissue in certain adults
and older children (142). Infants and young children should
be vaccinated in the anterolateral aspect of the thigh (47).
Side Effects and Adverse Reactions
When educating patients regarding potential side effects,
clinicians should emphasize that 1) inactivated influenza vac-
cine contains noninfectious killed viruses and cannot cause
influenza; and 2) coincidental respiratory disease unrelated to
influenza vaccination can occur after vaccination.
Local Reactions
In placebo-controlled studies among adults, the most fre-
quent side effect of vaccination is soreness at the vaccination
site (affecting 10%–64% of patients) that lasts <2 days
(13,143–145). These local reactions typically are mild and
rarely interfere with the person’s ability to conduct usual daily
activities. One study (62) reported 20%–28% of asthmatic
children aged 9 months–18 years had local pain and swelling
and another study (60) reported that 23% of children aged 6
months–4 years with chronic heart or lung disease had local
reactions. A different study (59) reported no difference in
local reactions among 53 children aged 6 months–6 years with
high-risk medical conditions or among 305 healthy children
aged 3–12 years in a placebo-controlled trial of inactivated
influenza vaccine. In a study of 12 children aged 5–32 months,
no substantial local or systemic reactions were noted (146).
Systemic Reactions
Fever, malaise, myalgia, and other systemic symptoms can
occur after vaccination and most often affect persons who have
had no prior exposure to the influenza virus antigens in the
vaccine (e.g., young children) (147,148). These reactions
begin 6–12 hours after vaccination and can persist for 1–2
days. Recent placebo-controlled trials demonstrate that among
TABLE 3. Influenza vaccine* dosage, by age group — United
States, 2002–2003 season
Age group† Dose Number of doses Route§
6–35 mos 0.25 mL 1 or 2¶ Intramuscular
3–8 yrs 0.50 mL 1 or 2¶ Intramuscular
>9 yrs 0.50 mL 1 Intramuscular
* Contains 15 mg each of A/Moscow/10/99 (H3N2)-like, A/New Caledonia/
20/99 (H1N1)-like, and B/Hong Kong/330/2001-like antigens. For the A/
Moscow/10/99 (H3N2)-like antigen, manufacturers will use the
antigenically equivalent A/Panama/2007/99 (H3N2) virus. For the B/Hong
Kong/330/2001-like antigen, the actual B strains that will be included in
the vaccine will be announced later. Manufacturers include Aventis Pasteur,
Inc. (Fluzone
®
 split); Evans Vaccines, Ltd. (Fluvirin™ purified surface
antigen vaccine); and Wyeth Lederle Laboratories (Flushield™ split).
Fluzone and Flushield are Food and Drug Administration approved for
use among persons aged >6 months. Fluvirin is approved for use among
persons aged >4 years. For further product information, call Aventis
Pasteur at 800-822-2463; Evans Vaccine, Ltd. at 800-200-4278; or Wyeth
Lederle at 800-358-7443.
†
Because of their decreased potential for causing febrile reactions, only
split-virus vaccines should be used for children aged <13 years. Split-
virus vaccine might be labeled as split, subvirion, or purified-surface-
antigen vaccine. Immunogenicity and side effects of split- and whole-
virus vaccines are similar among adults when vaccines are administered
at the recommended dosage. Whole-virus vaccine is not available in the
United States.
§
For adults and older children, the recommended site of vaccination is the
deltoid muscle. The preferred site for infants and young children is the
anterolateral aspect of the thigh.
¶
Two doses administered >1 month apart are recommended for children
aged <9 years who are receiving influenza vaccine for the first time.
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older persons and healthy young adults, administration of split-
virus influenza vaccine is not associated with higher rates of
systemic symptoms (e.g., fever, malaise, myalgia, and head-
ache) when compared with placebo injections (13,143–145).
Less information from published studies is available for chil-
dren compared with adults. In a study of 791 healthy children
(51), postvaccination fever was noted among 11.5% of chil-
dren aged 1–5 years, 4.6% among children aged 6–10 years,
and 5.1% among children aged 11–15 years. Among children
at high risk, one study of 52 children aged 6 months–4 years
reported fever among 27% and irritability and insomnia among
25% (60); a study among 33 children aged 6–18 months
reported that one child had irritability and one had a fever
and seizure after vaccination (149). No placebo comparison
was made in these studies. However, in pediatric trials of A/
New Jersey/76 swine influenza vaccine, no difference occurred
between placebo and split-virus vaccine groups in febrile reac-
tions after injection, although the vaccine was associated with
mild local tenderness or erythema (59). Limited data regard-
ing potential adverse events after influenza vaccination are
available from the Vaccine Adverse Event Reporting System
(VAERS). During January 1, 1991–July 16, 2001, VAERS
received 789 reports of adverse events among children aged
<18 years, including 89 reporting adverse events among chil-
dren aged 6–23 months. The number of influenza vaccine
doses received by children during this time period is unknown.
The most frequently reported events were fever, injection-site
reactions, and rash (unpublished data, CDC, 2001). Because
of the limitations of spontaneous reporting systems, determin-
ing causality for specific types of adverse events, with the
exception of injection-site reactions, is usually not possible by
using VAERS data alone.
Immediate — presumably allergic — reactions (e.g., hives,
angioedema, allergic asthma, and systemic anaphylaxis) rarely
occur after influenza vaccination (150). These reactions prob-
ably result from hypersensitivity to certain vaccine compo-
nents; the majority of reactions probably are caused by residual
egg protein. Although influenza vaccines contain only a lim-
ited quantity of egg protein, this protein can induce immedi-
ate hypersensitivity reactions among persons who have severe
egg allergy. Persons who have experienced hives, have had swell-
ing of the lips or tongue, or have experienced acute respiratory
distress or collapse after eating eggs should consult a physi-
cian for appropriate evaluation to help determine if vaccine
should be administered. Persons who have documented
immunoglobulin E (IgE)-mediated hypersensitivity to eggs —
including those who have had occupational asthma or other
allergic responses to egg protein — might also be at increased
risk for allergic reactions to influenza vaccine, and consulta-
tion with a physician should be considered. Protocols have
been published for safely administering influenza vaccine to
persons with egg allergies (151,152).
Hypersensitivity reactions to any vaccine component can
occur. Although exposure to vaccines containing thimerosal
can lead to induction of hypersensitivity, the majority of
patients do not experience reactions to thimerosal when it is
administered as a component of vaccines, even when patch or
intradermal tests for thimerosal indicate hypersensitivity
(153,154). When reported, hypersensitivity to thimerosal
usually has consisted of local, delayed-type hypersensitivity
reactions (153).
Guillain-Barré Syndrome
The 1976 swine influenza vaccine was associated with an
increased frequency of Guillain-Barré syndrome (GBS)
(155,156). Among persons who received the swine influenza
vaccine in 1976, the rate of GBS that exceeded the background
rate was <10 cases/1,000,000 persons vaccinated with the risk
of influenza vaccine-associated GBS higher among persons
aged >25 years than persons <25 years (155). Evidence for a
causal relationship of GBS with subsequent vaccines prepared
from other influenza viruses is unclear. Obtaining strong epi-
demiologic evidence for a possible limited increase in risk is
difficult for such a rare condition as GBS, which has an
annual incidence of 10–20 cases/1,000,000 adults (157), and
stretches the limits of epidemiologic investigation. More
definitive data probably will require the use of other method-
ologies (e.g., laboratory studies of the pathophysiology of GBS).
During three of four influenza seasons studied during 1977–
1991, the overall relative risk estimates for GBS after influ-
enza vaccination were slightly elevated but were not statistically
significant in any of these studies (158–160). However, in a
study of the 1992–1993 and 1993–1994 seasons, the overall
relative risk for GBS was 1.7 (95% confidence interval = 1.0–
2.8; p = 0.04) during the 6 weeks after vaccination, represent-
ing approximately 1 additional case of GBS/1,000,000 persons
vaccinated. The combined number of GBS cases peaked 2
weeks after vaccination (161). Thus, investigations to date
indicate no substantial increase in GBS associated with influ-
enza vaccines (other than the swine influenza vaccine in 1976)
and that, if influenza vaccine does pose a risk, it is probably
slightly more than 1 additional case/1,000,000 persons vacci-
nated. Cases of GBS after influenza infection have been
reported, but no epidemiologic studies have documented such
an association (162,163). Substantial evidence exists that sev-
eral infectious illnesses, most notably Campylobacter jejuni,
as well as upper-respiratory tract infections typically are
associated with GBS (157,164–166).
Even if GBS were a true side effect of vaccination in the
years after 1976, the estimated risk for GBS of approximately
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1 additional case/1,000,000 persons vaccinated is substantially
less than the risk for severe influenza, which could be
prevented by vaccination among all age groups, and chiefly
persons aged >65 years and those who have medical indica-
tions for influenza vaccination (Table 1) (see Hospitalizations
and Deaths from Influenza). The potential benefits of influ-
enza vaccination in preventing serious illness, hospitalization,
and death greatly outweigh the possible risks for developing
vaccine-associated GBS. The average case-fatality ratio for GBS
is 6% and increases with age (157,167). No evidence indi-
cates that the case-fatality ratio for GBS differs among vacci-
nated persons and those not vaccinated.
The incidence of GBS among the general population is low,
but persons with a history of GBS have a substantially greater
likelihood of subsequently developing GBS than persons with-
out such a history (158,168). Thus, the likelihood of coinci-
dentally developing GBS after influenza vaccination is expected
to be greater among persons with a history of GBS than among
persons with no history of this syndrome. Whether influenza
vaccination specifically might increase the risk for recurrence
of GBS is unknown; therefore, avoiding vaccinating persons
who are not at high risk for severe influenza complications
and who are known to have developed GBS within 6 weeks
after a previous influenza vaccination is prudent. As an alter-
native, physicians might consider the use of influenza antivi-
ral chemoprophylaxis for these persons. Although data are
limited, for the majority of persons who have a history of GBS
and who are at high risk for severe complications from influ-
enza, the established benefits of influenza vaccination justify
yearly vaccination.
Simultaneous Administration of Other
Vaccines, Including Childhood Vaccines
Adult target groups for influenza and pneumococcal polysac-
charide vaccination overlap considerably (169). For persons
at high risk who have not previously been vaccinated with
pneumococcal vaccine, health-care providers should strongly
consider administering pneumococcal polysaccharide and
influenza vaccines concurrently. Both vaccines can be admin-
istered at the same time at different sites without increasing
side effects (170,171). However, influenza vaccine is adminis-
tered each year, whereas pneumococcal vaccine is not. A
patient’s verbal history is acceptable for determining prior
pneumococcal vaccination status. When indicated, pneumo-
coccal vaccine should be administered to patients who are
uncertain regarding their vaccination history (169). No stud-
ies regarding the simultaneous administration of inactivated
influenza vaccine and other childhood vaccines have been
conducted. However, typically, inactivated vaccines do not
interfere with the immune response to other inactivated or
live vaccines (47), and children at high risk for influenza-
related complications, including those aged 6–23 months, can
receive influenza vaccine at the same time they receive other
routine vaccinations.
Strategies for Implementing These
Recommendations in Health-Care
Settings
Successful vaccination programs combine publicity and
education for health-care workers and other potential vaccine
recipients, a plan for identifying persons at high risk, use of
reminder/recall systems, and efforts to remove administrative
and financial barriers that prevent persons from receiving vac-
cine (19). Using standing orders programs is recommended
for long-term care facilities (e.g., nursing homes and skilled
nursing facilities) under the supervision of a medical director
to ensure the administration of recommended vaccinations
for adults. Other settings (e.g., inpatient and outpatient
facilities, managed care organizations, assisted living facilities,
correctional facilities, pharmacies, adult workplaces, and home
health-care agencies) are encouraged to introduce standing
orders programs as well (20). Persons for whom influenza vac-
cine is recommended can be identified and vaccinated in the
settings described in the following sections.
Outpatient Facilities Providing Ongoing Care
Staff in facilities providing ongoing medical care (e.g., phy-
sicians’ offices, public health clinics, employee health clinics,
hemodialysis centers, hospital specialty-care clinics, and out-
patient rehabilitation programs) should identify and label the
medical records of patients who should receive vaccination.
Vaccine should be offered during visits beginning in Septem-
ber and throughout the influenza season. The offer of vacci-
nation and its receipt or refusal should be documented in the
medical record. Patients for whom vaccination is recommended
who do not have regularly scheduled visits during the fall
should be reminded by mail, telephone, or other means of the
need for vaccination.
Outpatient Facilities Providing Episodic
or Acute Care
Beginning in each September, acute health-care facilities (e.g.,
emergency rooms and walk-in clinics) should offer vaccina-
tions to persons for whom vaccination is recommended or
provide written information regarding why, where, and how
to obtain the vaccine. This written information should be avail-
able in languages appropriate for the populations served by
the facility.
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Nursing Homes and Other Residential Long-
Term Care Facilities
During October and November each year, vaccination
should be routinely provided to all residents of chronic-care
facilities with the concurrence of attending physicians. Con-
sent for vaccination should be obtained from the resident or a
family member at the time of admission to the facility or any-
time afterwards. All residents should be vaccinated at one time,
preceding the influenza season. Residents admitted through
March after completion of the facility’s vaccination program
should be vaccinated at the time of admission.
Acute-Care Hospitals
Persons of all ages (including children) with high-risk con-
ditions and persons aged >50 years who are hospitalized at
any time during September–March should be offered and
strongly encouraged to receive influenza vaccine before they
are discharged. In one study, 39%–46% of patients hospital-
ized during the winter with influenza-related diagnoses had
been hospitalized during the preceding autumn (172). Thus,
the hospital is a setting in which persons at increased risk for
subsequent hospitalization can be identified and vaccinated.
Using standing orders in hospitals increases vaccination rates
among hospitalized persons (173).
Visiting Nurses and Others Providing Home
Care to Persons at High Risk
Beginning in September, nursing-care plans should identify
patients for whom vaccination is recommended, and vaccine
should be administered in the home, if necessary. Caregivers
and other persons in the household (including children) should
be referred for vaccination.
Other Facilities Providing Services to Persons
Aged >50 Years
Beginning in October, such facilities as assisted-living
facilities, retirement communities, and recreation centers
should offer unvaccinated residents and attendees vaccination
on site before the influenza season. Staff education should
emphasize the need for influenza vaccination.
Health-Care Workers
Beginning in October each year, health-care facilities should
offer influenza vaccinations to all personnel, including night
and weekend staff. Particular emphasis should be placed on
providing vaccinations for persons who care for members of
groups at high risk. Efforts should be made to educate health-
care workers regarding the benefits of vaccination and the
potential health consequences of influenza illness for them-
selves and their patients. Measures should be taken to provide
all health-care workers convenient access to influenza vacci-
nation at the work site, free of charge, as part of employee
health programs.
Influenza Vaccine Supply
In 2000, difficulties with growing and processing the influ-
enza A (H3N2) vaccine strain and other manufacturing prob-
lems resulted in substantial delays in the distribution of
2000–2001 influenza vaccine and fewer vaccine doses than
were distributed in 1999 (174). In 2001, a less severe delay
occurred. By December 2001, approximately 87.7 million
doses of vaccine were produced, more than in any year except
the 1976–1977 swine influenza vaccine campaign (175). In
July 2001, ACIP issued supplemental recommendations in
anticipation of the delay in 2001–2002 vaccine distribution
(176).
The possibility of future influenza vaccine delivery delays
or vaccine shortages remains. Steps to address such situations
include identification and implementation of ways to
strengthen the influenza vaccine supply, to improve targeted
delivery of vaccine to groups at high risk when delays or short-
ages are expected, and to encourage the administration of
vaccine throughout the influenza season every year.
Potential New Vaccine
Intranasally administered, cold-adapted, live, attenuated,
influenza virus vaccines (LAIVs) are being used in Russia and
have been under development in the United States since the
1960s (177–181). LAIVs have been studied as monovalent,
bivalent, and trivalent formulations (180,181). LAIVs consist
of live viruses that replicate in the upper respiratory tract, that
induce minimal symptoms (i.e., are attenuated) and that rep-
licate poorly at temperatures found in the lower respiratory
tract (i.e., are temperature-sensitive). Possible advantages of
LAIVs are their potential to induce a broad mucosal and
systemic immune response, ease of administration, and the
acceptability of an intranasal rather than intramuscular route
of administration. In a 5-year study that compared trivalent
inactivated vaccine and bivalent LAIVs (administered by nose
drops) and that used related but different vaccine strains, the
two vaccines were found to be approximately equivalent in
terms of effectiveness (51,182). In a 1996–1997 study of chil-
dren aged 15–71 months, an intranasally administered triva-
lent LAIV was 93% effective in preventing culture-positive
influenza A (H3N2) and B infections, reduced febrile otitis
media among vaccinated children by 30%, and reduced otitis
media with concomitant antibiotic use by 35% compared with
unvaccinated children (183). In a follow-up study during the
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1997–1998 season, the trivalent LAIV was 86% effective in
preventing culture-positive influenza among children, despite
a suboptimal match between the vaccine’s influenza A (H3N2)
component and the predominant circulating influenza A
(H3N2) virus (184). A study conducted among healthy adults
during the same season found a 9%–24% reduction in febrile
respiratory illnesses and a 13%–28% reduction in lost work
days (185). No study has directly compared the efficacy or
effectiveness of trivalent inactivated vaccine and trivalent LAIV.
An application for licensure of a LAIV is under review by FDA.
Recommendations for Using
Antiviral Agents for Influenza
Antiviral drugs for influenza are an adjunct to influenza vac-
cine for controlling and preventing influenza. However, these
agents are not a substitute for vaccination. Four licensed
influenza antiviral agents are available in the United States:
amantadine, rimantadine, zanamivir, and oseltamivir.
Amantadine and rimantadine are chemically related antivi-
ral drugs known as adamantanes with activity against influ-
enza A viruses but not influenza B viruses. Amantadine was
approved in 1966 for chemoprophylaxis of influenza A
(H2N2) infection and was later approved in 1976 for treat-
ment and chemoprophylaxis of influenza type A virus infec-
tions among adults and children aged >1 years. Rimantadine
was approved in 1993 for treatment and chemoprophylaxis of
infection among adults and prophylaxis among children.
Although rimantadine is approved only for chemoprophylaxis
of infection among children, certain experts in the manage-
ment of influenza consider it appropriate for treatment among
children (186).
Zanamivir and oseltamivir are chemically related antiviral
drugs known as neuraminidase inhibitors, which inhibit
neuraminidase and have activity against both influenza A and
B viruses. Both zanamivir and oseltamivir were approved in
1999 for treating uncomplicated influenza infections.
Zanamivir is approved for treating persons aged >7 years, and
oseltamivir is approved for treatment for persons aged >1 years.
In 2000, oseltamivir was approved for chemoprophylaxis of
influenza among persons aged >13 years.
The four drugs differ in terms of their pharmacokinetics,
side effects, routes of administration, approved age groups,
dosages, and costs. An overview of the indications, use,
administration, and known primary side effects of these medi-
cations is presented in the following sections. Information con-
tained in this report might not represent FDA approval or
approved labeling for the antiviral agents described. Package
inserts should be consulted for additional information.
Role of Laboratory Diagnosis
Appropriate treatment of patients with respiratory illness
depends on accurate and timely diagnosis. The early diagnosis
of influenza can reduce the inappropriate use of antibiotics
and provide the option of using antiviral therapy. However,
because certain bacterial infections can produce symptoms
similar to influenza, bacterial infections should be considered
and appropriately treated if suspected. In addition, bacterial
infections can occur as a complication of influenza.
Influenza surveillance information as well as diagnostic test-
ing can aid clinical judgment and guide treatment decisions.
The accuracy of clinical diagnosis of influenza based on symp-
toms alone is limited because symptoms from illness caused
by other pathogens can overlap considerably with influenza
(28–30). Influenza surveillance by state and local health
departments and CDC can provide information regarding the
presence of influenza viruses in the community. Surveillance
can also identify the predominant circulating types, subtypes,
and strains of influenza.
Diagnostic tests available for influenza include viral culture,
serology, rapid antigen testing, polymerase chain reaction
(PCR) and immunofluorescence (24). Sensitivity and speci-
ficity of any test for influenza might vary by the laboratory
that performs the test, the type of test used, and the type of
specimen tested. Among respiratory specimens for viral isola-
tion or rapid detection, nasopharyngeal specimens are typi-
cally more effective than throat swab specimens (187). As with
any diagnostic test, results should be evaluated in the context
of other clinical information available to the physician.
Commercial rapid diagnostic tests are available that can be
used by laboratories in outpatient settings to detect influenza
viruses within 30 minutes (24,188). These rapid tests differ in
the types of influenza viruses they can detect and whether they
can distinguish between influenza types. Different tests can
detect 1) only influenza A viruses; 2) both influenza A and B
viruses but not distinguish between the two types; or 3) both
influenza A and B and distinguish between the two. The types
of specimens acceptable for use (i.e., throat swab, nasal wash,
or nasal swab) also vary by test. The specificity and, in par-
ticular, the sensitivity of rapid tests are lower than for viral
culture and vary by test. Because of the lower sensitivity of the
rapid tests, physicians should consider confirming negative
tests with viral culture or other means. Package
inserts and the laboratory performing the test should be
consulted for more details. Additional information regarding
diagnostic testing is available at http://www.cdc.gov/ncidod/
diseases/flu/flu_dx_table.htm.
Despite the availability of rapid diagnostic tests, the collec-
tion of clinical specimens for viral culture is critical, because
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only culture isolates can provide specific information regard-
ing circulating influenza subtypes and strains. This informa-
tion is needed to compare current circulating influenza strains
with vaccine strains, to guide decisions regarding influenza
treatment and chemoprophylaxis, and to formulate vaccine
for the coming year. Virus isolates also are needed to monitor
the emergence of antiviral resistance and the emergence of novel
influenza A subtypes that might pose a pandemic threat.
Indications for Use
Treatment
When administered within 2 days of illness onset to other-
wise healthy adults, amantadine and rimantadine can reduce
the duration of uncomplicated influenza A illness, and
zanamivir and oseltamivir can reduce the duration of uncom-
plicated influenza A and B illness by approximately 1 day com-
pared with placebo (55,189–202). More clinical data are
available concerning the efficacy of zanamivir and oseltamivir
for treatment of influenza A infection than for treatment of
influenza B infection (191–206). However, in vitro data and
studies of treatment among mice and ferrets (207–214), in
addition to clinical studies, have documented that zanamivir
and oseltamivir have activity against influenza B viruses
(195,199–201,205,206).
None of the four antiviral agents has been demonstrated to
be effective in preventing serious influenza-related complica-
tions (e.g., bacterial or viral pneumonia or exacerbation of
chronic diseases). Evidence for the effectiveness of these four
antiviral drugs is based principally on studies of patients with
uncomplicated influenza (215). Data are limited and incon-
clusive concerning the effectiveness of amantadine,
rimantadine, zanamivir, and oseltamivir for treatment of
influenza among persons at high risk for serious complica-
tions of influenza (189,191,192,194,195,202,216–220).
Fewer studies of the efficacy of influenza antivirals have been
conducted among pediatric populations compared with adults
(189,192,198,199,218,221,222). One study of oseltamivir
treatment documented a decreased incidence of otitis media
among children (199).
To reduce the emergence of antiviral drug-resistant viruses,
amantadine or rimantadine therapy for persons with influ-
enza A illness should be discontinued as soon as clinically
warranted, typically after 3–5 days of treatment or within
24–48 hours after the disappearance of signs and symptoms.
The recommended duration of treatment with either zanamivir
or oseltamivir is 5 days.
Chemoprophylaxis
Chemoprophylactic drugs are not a substitute for vaccina-
tion, although they are critical adjuncts in the prevention and
control of influenza. Both amantadine and rimantadine are
indicated for the chemoprophylaxis of influenza A infection,
but not influenza B. Both drugs are approximately 70%–90%
effective in preventing illness from influenza A infection
(55,189,218). When used as prophylaxis, these antiviral agents
can prevent illness while permitting subclinical infection and
the development of protective antibody against circulating
influenza viruses. Therefore, certain persons who take these
drugs will develop protective immune responses to circulating
influenza viruses. Amantadine and rimantadine do not inter-
fere with the antibody response to the vaccine (189). Both
drugs have been studied extensively among nursing home
populations as a component of influenza outbreak control
programs, which can limit the spread of influenza within
chronic care institutions (189,217,223–225).
Among the neuraminidase inhibitor antivirals, zanamivir
and oseltamivir, only oseltamivir has been approved for pro-
phylaxis, but community studies of healthy adults indicate
that both drugs are similarly effective in preventing febrile,
laboratory-confirmed influenza illness (efficacy: zanamivir,
84%; oseltamivir, 82%) (226,227). Both antiviral agents have
also been reported to prevent influenza illness among persons
given chemoprophylaxis after a household member was diag-
nosed with influenza (205,228). Experience with prophylac-
tic use of these agents in institutional settings or among patients
with chronic medical conditions is limited in comparison with
the adamantanes (201,220,229–232). One 6-week study of
oseltamivir prophylaxis among nursing home residents
reported a 92% reduction in influenza illness (201,233). Use
of zanamivir has not been reported to impair the immuno-
logic response to influenza vaccine (200,234). Data are not
available on the efficacy of any of the four antiviral agents in
preventing influenza among severely immune compromised
persons.
When determining the timing and duration for administer-
ing influenza antiviral medications for prophylaxis, factors
related to cost, compliance, and potential side effects should
be considered. To be maximally effective as prophylaxis, the
drug must be taken each day for the duration of influenza
activity in the community. However, to be most cost-
effective, one study of amantadine or rimantadine prophy-
laxis reported that the drugs should be taken only during the
period of peak influenza activity in a community (235).
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Persons at High Risk Who Are Vaccinated After Influ-
enza Activity Has Begun. Persons at high risk for complica-
tions of influenza still can be vaccinated after an outbreak of
influenza has begun in a community. However, the develop-
ment of antibodies in adults after vaccination can take
approximately 2 weeks (134,135). When influenza vaccine is
administered while influenza viruses are circulating, chemo-
prophylaxis should be considered for persons at high risk dur-
ing the time from vaccination until immunity has developed.
Children aged <9 years who receive influenza vaccine for the
first time can require 6 weeks of prophylaxis (i.e., prophylaxis
for 4 weeks after the first dose of vaccine and an additional 2
weeks of prophylaxis after the second dose).
Persons Who Provide Care to Those at High Risk. To
reduce the spread of virus to persons at high risk during com-
munity or institutional outbreaks, chemoprophylaxis during
peak influenza activity can be considered for unvaccinated
persons who have frequent contact with persons at high risk.
Persons with frequent contact include employees of hospitals,
clinics, and chronic-care facilities, household members, visit-
ing nurses, and volunteer workers. If an outbreak is caused by
a variant strain of influenza that might not be controlled by
the vaccine, chemoprophylaxis should be considered for all
such persons, regardless of their vaccination status.
Persons Who Have Immune Deficiency. Chemoprophy-
laxis can be considered for persons at high risk who are
expected to have an inadequate antibody response to influ-
enza vaccine. This category includes persons infected with HIV,
chiefly those with advanced HIV disease. No published data
are available concerning possible efficacy of chemoprophylaxis
among persons with HIV infection or interactions with other
drugs used to manage HIV infection. Such patients should be
monitored closely if chemoprophylaxis is administered.
Other Persons. Chemoprophylaxis throughout the influ-
enza season or during peak influenza activity might be appro-
priate for persons at high risk who should not be vaccinated.
Chemoprophylaxis can also be offered to persons who wish to
avoid influenza illness. Health-care providers and patients
should make this decision on an individual basis.
Control of Influenza Outbreaks in Institutions
Using antiviral drugs for treatment and prophylaxis of
influenza is a key component of institutional outbreak con-
trol. In addition to using antiviral medications, other outbreak
control measures include instituting droplet precautions and
establishing cohorts of patients with confirmed or suspected
influenza, re-offering influenza vaccinations to unvaccinated
staff and patients, restricting staff movement between wards
or buildings, and restricting contact between ill staff or
visitors and patients (236–238) (for additional information
regarding outbreak control in specific settings, see Additional
Information Regarding Influenza Infection Control Among
Specific Populations).
The majority of published reports concerning the use of
antiviral agents to control institutional influenza outbreaks
are based on studies of influenza A outbreaks among nursing
home populations where amantadine or rimantadine were used
(189,217,223–225,235). Less information is available con-
cerning the use of neuraminidase inhibitors in influenza A or
B institutional outbreaks (220,231,233). When confirmed or
suspected outbreaks of influenza occur in institutions that
house persons at high risk, chemoprophylaxis should be started
as early as possible to reduce the spread of the virus. In these
situations, having preapproved orders from physicians or plans
to obtain orders for antiviral medications on short notice is
useful.
When institutional outbreaks occur, chemoprophylaxis
should be administered to all residents — regardless of whether
they received influenza vaccinations during the previous fall
— and should continue for >2 weeks. If surveillance indicates
that new cases continue to occur, chemoprophylaxis should
be continued until approximately 1 week after the end of the
outbreak. The dosage for each resident should be determined
individually. Chemoprophylaxis also can be offered to unvac-
cinated staff who provide care to persons at high risk. Prophy-
laxis should be considered for all employees, regardless of their
vaccination status, if the outbreak is caused by a variant strain
of influenza that is not well-matched by the vaccine.
In addition to nursing homes, chemoprophylaxis also can
be considered for controlling influenza outbreaks in other
closed or semiclosed settings (e.g., dormitories or other set-
tings where persons live in close proximity). For example,
chemoprophylaxis with rimantadine has been used success-
fully to control an influenza A outbreak aboard a cruise ship
(239).
To limit the potential transmission of drug-resistant virus
during institutional outbreaks, whether in chronic or acute-
care settings or other closed settings, measures should be taken
to reduce contact as much as possible between persons taking
antiviral drugs for treatment and other persons, including those
taking chemoprophylaxis (see Antiviral Drug-Resistant Strains
of Influenza).
Dosage
Dosage recommendations vary by age group and medical
conditions (Table 4).
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Children
Amantadine. Use of amantadine among children aged <1
year has not been adequately evaluated. The FDA-approved
dosage for children aged 1–9 years for treatment and prophy-
TABLE 4. Recommended daily dosage of influenza antiviral medications for treatment and prophylaxis
Age group (yrs)
Antiviral agent 1–6 7–9 10–12 13–64 >65
NOTE: Amantadine manufacturers include Endo Pharmaceuticals (Symmetrel® — tablet and syrup); Geneva Pharms Tech and Rosemont (Amantadine HCL
— capsule); and Alpharma, Copley Pharmaceutical, HiTech Pharma, Mikart, Morton Grove, and Pharmaceutical Associates (Amantadine HCL — syrup).
Rimantadine is manufactured by Forest Laboratories (Flumadine® — tablet and syrup) and Corepharma (Rimantadine HCL — tablet). Zanamivir is
manufactured by GlaxoSmithKline (Relenza® — inhaled powder). Oseltamivir is manufactured by Hoffman-LaRoche, Inc. (Tamiflu® — tablet). This
information is based on data published by the Food and Drug Administration (FDA), which is available at www.fda.gov.
* The drug package insert should be consulted for dosage recommendations for administering amantadine to persons with creatinine clearance <50 mL/
min/1.73m2.
† 5 mg/kg of amantadine or rimantadine syrup = 1 tsp/22 lbs.
§ Children aged >10 years who weigh <40 kg should be administered amantadine or rimantadine at a dosage of 5 mg/kg/day.
¶ A reduction in dosage to 100 mg/day of rimantadine is recommended for persons who have severe hepatic dysfunction or those with creatinine clearance
<10 mL/min. Other persons with less severe hepatic or renal dysfunction taking 100 mg/day of rimantadine should be observed closely, and the dosage
should be reduced or the drug discontinued, if necessary.
** Only approved by FDA for treatment among adults.
†† Not applicable.
§§ Rimantadine is approved by FDA for treatment among adults. However, certain specialists in the management of influenza consider rimantadine appro-
priate for treatment among children (see American Academy of Pediatrics. 2000 red book American Academy of Pediatrics. 2000 red book: report of the
Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2000.).
¶¶ Older nursing-home residents should be administered only 100 mg/day of rimantadine. A reduction in dosage to 100 mg/day should be considered for all
persons aged >65 years, if they experience possible side effects when taking 200 mg/day.
*** Zanamivir is administered through inhalation by using a plastic device included in the medication package. Patients will benefit from instruction and
demonstration of correct use of the device.
††† Zanamivir is not approved for prophylaxis.
§§§ A reduction in the dose of oseltamivir is recommended for persons with creatinine clearance <30 mL/min.
¶¶¶ The dose recommendation for children who weigh <15 kg is 30 mg twice a day. For children who weigh >15–23 kg, the dose is 45 mg twice a day. For
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laxis is 4.4–8.8 mg/kg/day, not to exceed 150 mg/day. Although
further studies are needed to determine the optimal dosage
for children aged 1–9 years, physicians should consider
prescribing only 5 mg/kg/day (not to exceed 150 mg/day) to
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reduce the risk for toxicity. The approved dosage for children
aged >10 years is 200 mg/day (100 mg twice a day); however,
for children weighing <40 kg, prescribing 5 mg/kg/day,
regardless of age, is advisable (219,240).
Rimantadine. Rimantadine is approved for prophylaxis
among children aged >1 years and for treatment and prophy-
laxis among adults. Although rimantadine is approved only
for prophylaxis of infection among children, certain special-
ists in the management of influenza consider rimantadine
appropriate for treatment among children (186). Use of
rimantadine among children aged <1 year has not been
adequately evaluated. Rimantadine should be administered in
one or two divided doses at a dosage of 5 mg/kg/day, not to
exceed 150 mg/day for children aged 1–9 years. The approved
dosage for children aged >10 years is 200 mg/day (100 mg
twice a day); however, for children weighing <40 kg, prescrib-
ing 5 mg/kg/day, regardless of age, is recommended (241).
Zanamivir. Zanamivir is approved for treatment among chil-
dren aged >7 years. The recommended dosage of zanamivir
for treatment of influenza is two inhalations (one 5-mg blister
per inhalation for a total dose of 10 mg) twice daily (approxi-
mately 12 hours apart) (200).
Oseltamivir. Oseltamivir is approved for treatment among
persons aged >1 year and for chemoprophylaxis among per-
sons age >13 years. Recommended treatment dosages for chil-
dren vary by the weight of the child: the dosage
recommendation for children who weigh <15 kg is 30 mg
twice a day; for children weighing >15–23 kg, the dosage is
45 mg twice a day; for those weighing >23–40 kg, the dosage
is 60 mg twice a day; and for children weighing >40 kg, the
dosage is 75 mg twice a day. The treatment dosage for persons
>13 years is 75 mg twice daily. For children >13 years, the
recommended dosage for prophylaxis is 75 mg once a day
(201).
Persons Aged >65 Years
Amantadine. The daily dosage of amantadine for persons
aged >65 years should not exceed 100 mg for prophylaxis or
treatment, because renal function declines with increasing age.
For certain older persons, the dosage should be further
reduced.
Rimantadine. Among older persons, the incidence and
severity of central nervous system (CNS) side effects are sub-
stantially lower among those taking rimantadine at a dosage
of 100 mg/day than among those taking amantadine at dos-
ages adjusted for estimated renal clearance (242). However,
chronically ill older persons have had a higher incidence of
CNS and gastrointestinal symptoms and serum concentrations
two to four times higher than among healthy, younger per-
sons when rimantadine has been administered at a dosage of
200 mg/day (189).
For prophylaxis among persons aged >65 years, the recom-
mended dosage is 100 mg/day. For treatment of older persons
in the community, a reduction in dosage to 100 mg/day should
be considered if they experience side effects when taking a
dosage of 200 mg/day. For treatment of older nursing home
residents, the dosage of rimantadine should be reduced to 100
mg/day (241).
Zanamivir and Oseltamivir. No reduction in dosage is
recommended on the basis of age alone.
Persons with Impaired Renal Function
Amantadine. A reduction in dosage is recommended for
patients with creatinine clearance <50 mL/min/1.73m2. Guide-
lines for amantadine dosage on the basis of creatinine clear-
ance are found in the package insert. Because recommended
dosages on the basis of creatinine clearance might provide only
an approximation of the optimal dose for a given patient, such
persons should be observed carefully for adverse reactions. If
necessary, further reduction in the dose or discontinuation of
the drug might be indicated because of side effects. Hemodi-
alysis contributes minimally to amantadine clearance
(240,243).
Rimantadine. A reduction in dosage to 100 mg/day is rec-
ommended for persons with creatinine clearance <10 mL/min.
Because of the potential for accumulation of rimantadine and
its metabolites, patients with any degree of renal insufficiency,
including older persons, should be monitored for adverse
effects, and either the dosage should be reduced or the drug
should be discontinued, if necessary. Hemodialysis contrib-
utes minimally to drug clearance (244).
Zanamivir. Limited data are available regarding the safety
and efficacy of zanamivir for patients with impaired renal func-
tion. Among patients with renal failure who were adminis-
tered a single intravenous dose of zanamivir, decreases in renal
clearance, increases in half-life, and increased systemic expo-
sure to zanamivir were observed (200,245). However, a lim-
ited number of healthy volunteers who were administered high
doses of intravenous zanamivir tolerated systemic levels of
zanamivir that were substantially higher than those resulting
from administration of zanamivir by oral inhalation at the
recommended dose (246,247). On the basis of these consid-
erations, the manufacturer recommends no dose adjustment
for inhaled zanamivir for a 5-day course of treatment for
patients with either mild-to-moderate or severe impairment
in renal function (200).
Oseltamivir. Serum concentrations of oseltamivir carboxy-
late (GS4071), the active metabolite of oseltamivir, increase
with declining renal function (201,204). For patients with
creatinine clearance of 10–30 mL/min (201), a reduction of
the treatment dosage of oseltamivir to 75 mg once daily and
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in the prophylaxis dosage to 75 mg every other day is recom-
mended. No treatment or prophylaxis dosing recommenda-
tions are available for patients undergoing routine renal dialysis
treatment.
Persons with Liver Disease
Amantadine. No increase in adverse reactions to amanta-
dine has been observed among persons with liver disease. Rare
instances of reversible elevation of liver enzymes among
patients receiving amantadine have been reported, although a
specific relationship between the drug and such changes has
not been established (248).
Rimantadine. A reduction in dosage to 100 mg/day is
recommended for persons with severe hepatic dysfunction.
Zanamivir and Oseltamivir. Neither of these medications
has been studied among persons with hepatic dysfunction.
Persons with Seizure Disorders
Amantadine. An increased incidence of seizures has been
reported among patients with a history of seizure disorders
who have received amantadine (249). Patients with seizure
disorders should be observed closely for possible increased
seizure activity when taking amantadine.
Rimantadine. Seizures (or seizure-like activity) have been
reported among persons with a history of seizures who were
not receiving anticonvulsant medication while taking
rimantadine (250). The extent to which rimantadine might
increase the incidence of seizures among persons with seizure
disorders has not been adequately evaluated.
Zanamivir and Oseltamivir. Seizure events have been
reported during postmarketing use of zanamivir and
oseltamivir, although no epidemiologic studies have reported
any increased risk for seizures with either zanamivir or
oseltamivir use.
Route
Amantadine, rimantadine, and oseltamivir are administered
orally. Amantadine and rimantadine are available in tablet or
syrup form, and oseltamivir is available in capsule or oral sus-
pension form (178,179). Zanamivir is available as a dry pow-
der that is self-administered via oral inhalation by using a plastic
device included in the package with the medication. Patients
will benefit from instruction and demonstration of correct
use of this device (200).
Pharmacokinetics
Amantadine
Approximately 90% of amantadine is excreted unchanged
in the urine by glomerular filtration and tubular secretion
(223,251–254). Thus, renal clearance of amantadine is reduced
substantially among persons with renal insufficiency, and
dosages might need to be decreased (see Dosage) (Table 4).
Rimantadine
Approximately 75% of rimantadine is metabolized by the
liver (218). The safety and pharmacokinetics of rimantadine
among persons with liver disease have been evaluated only
after single-dose administration (218,255). In a study of per-
sons with chronic liver disease (the majority with stabilized
cirrhosis), no alterations in liver function were observed after
a single dose. However, for persons with severe liver dysfunc-
tion, the apparent clearance of rimantadine was 50% lower
than that reported for persons without liver disease (241).
Rimantadine and its metabolites are excreted by the kid-
neys. The safety and pharmacokinetics of rimantadine among
patients with renal insufficiency have been evaluated only
after single-dose administration (218,244). Further studies are
needed to determine multiple-dose pharmacokinetics and the
most appropriate dosages for patients with renal insufficiency.
In a single-dose study of patients with anuric renal failure, the
apparent clearance of rimantadine was approximately 40%
lower, and the elimination half-life was approximately 1.6-
fold greater than that among healthy persons of the same age
(244). Hemodialysis did not contribute to drug clearance. In
studies of persons with less severe renal disease, drug clearance
was also reduced, and plasma concentrations were higher than
those among control patients without renal disease who were
the same weight, age, and sex (241,256).
Zanamivir
In studies of healthy volunteers, approximately 7%–21% of
the orally inhaled zanamivir dose reached the lungs, and 70%–
87% was deposited in the oropharynx (200,257). Approxi-
mately 4%–17% of the total amount of orally inhaled
zanamivir is systemically absorbed. Systemically absorbed
zanamivir has a half-life of 2.5–5.1 hours and is excreted
unchanged in the urine. Unabsorbed drug is excreted in the
feces (200,247).
Oseltamivir
Approximately 80% of orally administered oseltamivir is
absorbed systemically (204). Absorbed oseltamivir is metabo-
lized to oseltamivir carboxylate, the active neuraminidase in-
hibitor, primarily by hepatic esterases. Oseltamivir carboxylate
has a half-life of 6–10 hours and is excreted in the urine by
glomerular filtration and tubular secretion via the anionic path-
way (201,258). Unmetabolized oseltamivir also is excreted in
the urine by glomerular filtration and tubular secretion (258).
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Side Effects and Adverse Reactions
When considering the use of influenza antiviral medications
(i.e., choice of antiviral drug, dosage, and duration of therapy),
clinicians must consider the patient’s age, weight, and renal
function (Table 4); presence of other medical conditions;
indications for use (i.e., prophylaxis or therapy); and the
potential for interaction with other medications.
Amantadine and Rimantadine
Both amantadine and rimantadine can cause CNS and gas-
trointestinal side effects when administered to young, healthy
adults at equivalent dosages of 200 mg/day. However, inci-
dence of CNS side effects (e.g., nervousness, anxiety, insom-
nia, difficulty concentrating, and lightheadedness) is higher
among persons taking amantadine than among those taking
rimantadine (259). In a 6-week study of prophylaxis among
healthy adults, approximately 6% of participants taking
rimantadine at a dosage of 200 mg/day experienced >1 CNS
symptoms, compared with approximately 13% of those tak-
ing the same dosage of amantadine and 4% of those taking
placebo (259). A study of older persons also demonstrated
fewer CNS side effects associated with rimantadine compared
with amantadine (242). Gastrointestinal side effects (e.g., nau-
sea and anorexia) occur in approximately 1%–3% of persons
taking either drug, compared with 1% of persons receiving
the placebo (259).
Side effects associated with amantadine and rimantadine are
usually mild and cease soon after discontinuing the drug. Side
effects can diminish or disappear after the first week, despite
continued drug ingestion. However, serious side effects have
been observed (e.g., marked behavioral changes, delirium,
hallucinations, agitation, and seizures) (240,249). These more
severe side effects have been associated with high plasma drug
concentrations and have been observed most often among
persons who have renal insufficiency, seizure disorders, or cer-
tain psychiatric disorders and among older persons who have
been taking amantadine as prophylaxis at a dosage of 200 mg/
day (223). Clinical observations and studies have indicated
that lowering the dosage of amantadine among these persons
reduces the incidence and severity of such side effects (Table
4). In acute overdosage of amantadine, CNS, renal, respira-
tory, and cardiac toxicity, including arrhythmias, have been
reported (240). Because rimantadine has been marketed for a
shorter period than amantadine, its safety among certain
patient populations (e.g., chronically ill and elderly persons)
has been evaluated less frequently. Because amantadine has
anticholinergic effects and might cause mydriasis, it should
not be used for patients with untreated angle closure
glaucoma (240).
Zanamivir
In a study of zanamivir treatment of influenza-like illness
among persons with asthma or chronic obstructive pulmo-
nary disease where study medication was administered after
using a B2-agonist, 13% of patients receiving zanamivir and
14% of patients who received placebo (inhaled powdered lac-
tose vehicle) experienced a >20% decline in forced expiratory
volume in 1 second (FEV1) after treatment (200,202). How-
ever, in a study of persons with mild or moderate asthma who
did not have influenza-like illness, 1 of 13 patients experi-
enced bronchospasm after administration of zanamivir (200).
In addition, during postmarketing surveillance, cases of respi-
ratory function deterioration after inhalation of zanamivir have
been reported. Certain patients had underlying airways dis-
ease (e.g., asthma or chronic obstructive pulmonary disease).
Because of the risk for serious adverse events and because the
efficacy has not been demonstrated among this population,
zanamivir is generally not recommended for treatment for
patients with underlying airway disease (200). If physicians
decide to prescribe zanamivir to patients with underlying
chronic respiratory disease after carefully considering poten-
tial risks and benefits, the drug should be used with caution
under conditions of proper monitoring and supportive care,
including the availability of short-acting bronchodilators (215).
Patients with asthma or chronic obstructive pulmonary dis-
ease who use zanamivir are advised to 1) have a fast-acting
inhaled bronchodilator available when inhaling zanamivir and
2) stop using zanamivir and contact their physician if they
develop difficulty breathing (200). No clear evidence is avail-
able regarding the safety or efficacy of zanamivir for persons
with underlying respiratory or cardiac disease or for persons
with complications of acute influenza (215). Allergic reactions,
including oropharyngeal or facial edema, have also been
reported during postmarketing surveillance (200,220).
In clinical treatment studies of persons with uncomplicated
influenza, the frequencies of adverse events were similar for
persons receiving inhaled zanamivir and those receiving pla-
cebo (i.e., inhaled lactose vehicle alone) (190–195,220). The
most common adverse events reported by both groups were
diarrhea; nausea; sinusitis; nasal signs and symptoms; bron-
chitis; cough; headache; dizziness; and ear, nose, and throat
infections. Each of these symptoms was reported by <5% of
persons in the clinical treatment studies combined (200).
Oseltamivir
Nausea and vomiting were reported more frequently among
adults receiving oseltamivir for treatment (nausea without
vomiting, approximately 10%; vomiting, approximately 9%)
than among persons receiving placebo (nausea without vom-
iting, approximately 6%; vomiting, approximately 3%)
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(196,197,201,260). Among children treated with oseltamivir,
14.3% had vomiting, compared with 8.5% of placebo recipi-
ents. Overall, 1% discontinued the drug secondary to this side
effect (199), whereas a limited number of adults enrolled in
clinical treatment trials of oseltamivir discontinued treatment
because of these symptoms (201). Similar types and rates of
adverse events were found in studies of oseltamivir prophy-
laxis (201). Nausea and vomiting might be less severe if
oseltamivir is taken with food (201,260).
Use During Pregnancy
No clinical studies have been conducted regarding the safety
or efficacy of amantadine, rimantadine, zanamivir, or
oseltamivir for pregnant women; only two cases of amanta-
dine use for severe influenza illness during the third trimester
have been reported (105,106). However, both amantadine and
rimantadine have been demonstrated in animal studies to be
teratogenic and embryotoxic when administered at very high
doses (240,241). Because of the unknown effects of influenza
antiviral drugs on pregnant women and their fetuses, these
four drugs should be used during pregnancy only if the poten-
tial benefit justifies the potential risk to the embryo or fetus
(see package inserts for additional information
[200,201,240,241]).
Drug Interactions
Careful observation is advised when amantadine is admin-
istered concurrently with drugs that affect CNS, especially
CNS stimulants. Concomitant administration of antihista-
mines or anticholinergic drugs can increase the incidence
of adverse CNS reactions (189). No clinically significant
interactions between rimantadine and other drugs have been
identified.
Clinical data are limited regarding drug interactions with
zanamivir. However, no known drug interactions have been
reported, and no clinically important drug interactions have
been predicted on the basis of in vitro data and data from
studies involving rats (200,261).
Limited clinical data are available regarding drug inter-
actions with oseltamivir. Because oseltamivir and oseltamivir
carboxylate are excreted in the urine by glomerular filtration
and tubular secretion via the anionic pathway, a potential
exists for interaction with other agents excreted by this path-
way. For example, coadministration of oseltamivir and
probenecid resulted in reduced clearance of oseltamivir car-
boxylate by approximately 50% and a corresponding approxi-
mate twofold increase in the plasma levels of oseltamivir
carboxylate (201,258).
No published data are available concerning the safety or
efficacy of using combinations of any of these four influenza
antiviral drugs. For more detailed information concerning
potential drug interactions for any of these influenza antiviral
drugs, package inserts should be consulted.
Antiviral Drug-Resistant Strains
of Influenza
Amantadine-resistant viruses are cross-resistant to
rimantadine and vice versa (262). Drug-resistant viruses can
appear in approximately one third of patients when either
amantadine or rimantadine is used for therapy (222,263,264).
During the course of amantadine or rimantadine therapy,
resistant influenza strains can replace sensitive strains within
2–3 days of starting therapy (263,265). Resistant viruses have
been isolated from persons who live at home or in an institu-
tion where other residents are taking or have recently taken
amantadine or rimantadine as therapy (266,267); however,
the frequency with which resistant viruses are transmitted and
their impact on efforts to control influenza are unknown.
Amantadine- and rimantadine-resistant viruses are not more
virulent or transmissible than sensitive viruses (268). The
screening of epidemic strains of influenza A has rarely detected
amantadine- and rimantadine-resistant viruses (263,269,270).
Persons who have influenza A infection and who are treated
with either amantadine or rimantadine can shed sensitive
viruses early in the course of treatment and later shed drug-
resistant viruses, especially after 5–7 days of therapy (222).
Such persons can benefit from therapy even when resistant
viruses emerge.
Resistance to zanamivir and oseltamivir can be induced in
influenza A and B viruses in vitro (271–278), but induction
of resistance requires multiple passages in cell culture. By con-
trast, resistance to amantadine and rimantadine in vitro can
be induced with fewer passages in cell culture (279,280).
Development of viral resistance to zanamivir and oseltamivir
during treatment has been identified but does not appear to
be frequent (201,281–284). In clinical treatment studies
using oseltamivir, 1.3% of posttreatment isolates from
patients aged >13 years and 8.6% among patients aged 1–12
years had decreased susceptibility to oseltamivir (201). No
isolates with reduced susceptibility to zanamivir have been
reported from clinical trials, although the number of post-
treatment isolates tested is limited (285), and the risk for emer-
gence of zanamivir-resistant isolates cannot be quantified (200).
Only one clinical isolate with reduced susceptibility to
zanamivir, obtained from an immunocompromised child on
prolonged therapy, has been reported (282). Available diag-
nostic tests are not optimal for detecting clinical resistance to
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the neuraminidase inhibitor antiviral drugs, and additional
tests are being developed. (285,286). Postmarketing surveil-
lance for neuraminidase inhibitor-resistant influenza viruses
is being conducted (287).
Sources of Information Regarding
Influenza and Its Surveillance
Information regarding influenza surveillance, prevention,
detection, and control is available on CDC/NCID’s website
at http://www.cdc.gov/ncidod/diseases/flu/fluvirus.htm. Sur-
veillance information is available through the CDC Voice
Information System (influenza update) at 888-232-3228 or
CDC Fax Information Service at 888-232-3299. During
October–May, surveillance information is updated at least
every other week. In addition, periodic updates regarding
influenza are published in the MMWR (weekly). Additional
information regarding influenza vaccine can be obtained at
CDC/NIP’s website at http://www.cdc.gov/nip/flu or by call-
ing the NIP hotline at 800-232-2522 (English) or 800-232-
0233 (Spanish). State and local health departments should be
consulted concerning availability of influenza vaccine, access
to vaccination programs, information related to state or local
influenza activity, and for reporting influenza outbreaks and
receiving advice concerning outbreak control.
Additional Information Regarding
Influenza Infection Control Among
Specific Populations
Each year, ACIP provides general, annually updated infor-
mation regarding the control and prevention of influenza.
Other reports on the control and prevention of influenza
among specific populations (e.g., immunocompromised per-
sons, health-care workers, hospitals, and travelers) are also avail-
able in the following publications:
• Garner JS, for the Hospital Infection Control Practices
Advisory Committee. Guideline for isolation precautions
in hospitals. Infect Control Hosp Epidemiol 1996;17: 53–80.
• Tablan OC, Anderson LJ, Arden NH, et al., for the Hos-
pital Infection Control Practices Advisory Committee.
Guideline for prevention of nosocomial pneumonia.
Infect Control Hosp Epidemiol 1994;15:587–627.
• Bolyard EA, Tablan OC, Williams WW, et al., for
the Hospital Infection Control Practices Advisory
Committee. Guideline for infection control in health care
personnel. Am J Infect Control 1998;26:289–354.
• Bradley SF, for the Long-Term–Care Committee of the
Society for Healthcare Epidemiology of America. Preven-
tion of influenza in long-term care facilities. Infect
Control Hosp Epidemiol 1999;20:629–37.
• Sneller V-P, Izurieta H, Bridges C, et al. Prevention and
control of vaccine-preventable diseases in long-term care
facilities. Journal of the American Medical Directors
Association 2000;1(Suppl):S2–37.
• American Academy of Pediatrics. 2000 red book: report
of the Committee on Infectious Diseases. 25th ed. Elk
Grove Village, IL: American Academy of Pediatrics, 2000.
• CDC. General recommendations on immunization: rec-
ommendations of the Advisory Committee on Immuni-
zation Practices (ACIP) and the American Academy of
Family Practitioners (AAFP). MMWR 2002;51(No. RR-
2):1–35.
• Bodnar UR, Maloney SA, Fielding KL, et al. Preliminary
guidelines for the prevention and control of influenza-
like illness among passengers and crew members on cruise
ships. Atlanta, GA: US Department of Health and
Human Services, CDC, National Center for Infectious
Diseases, 1999.
• CDC. General recommendations for preventing influenza
A infection among travelers. Atlanta, GA: US Department
of Health and Human Services, CDC, 2001. Available at
http://www.cdc.gov/travel/feb99.htm.
• US Public Health Service (USPHS) and Infectious
Diseases Society of America (IDSA). USPHS/IDSA
Prevention of Opportunistic Infections Working Group.
2001 USPHS/IDSA guidelines for the prevention of
opportunistic infections in persons infected with human
immunodeficiency virus. Final November 28, 2001;
1–65. Available at http://www.hivatis.org/guidelines/
other/OIs/OIGNov27.pdf.
• CDC. Detection & control of influenza outbreaks in acute
care facilities. Atlanta, GA: US Department of Health and
Human Services, CDC, National Center for Infectious
Diseases, 2001. Available at http://www.cdc.gov/ncidod/
hip/INFECT/FluBook2001.pdf.
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